Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members
17 Giugno 2020 - 06:15PM
Valneva Announces
Successful Outcome of its AGM and the Appointment of two new
Supervisory Board Members
Saint-Herblain (France), June 17, 2020 –
Valneva SE (“Valneva” or “the Company”), a specialty vaccine
company, announced today that all the resolutions recommended by
the Management Board were approved by the shareholders at its
Annual General Meeting (AGM) held behind closed doors in Nantes on
June 17, 2020.
Among the resolutions approved during the AGM
were the 2019 financial statements, delegations for the management
board to increase the share capital and/or to issue financial
instruments, and the appointment, for a three-year term, of two new
Supervisory Board members.
Ms. Johanna Willemina Pattenier, MD, PhD, based
in Switzerland has a proven track record of more than 25 years in
the pharmaceutical industry. She spent most of her career in
vaccines leadership roles across commercial, clinical development,
medical, market access functions as well as general management.
Dr.Pattenier successfully led late stage development and market
access programs for new vaccines, including HPV and Meningitis B.
Most recently, she served as General Manager of Novartis Vaccines
and Diagnostics (now a GlaxoSmithKline (GSK) company) in Basel and
GSK / Novartis vaccines integration lead. Prior to that, Dr.
Pattenier’s international career included commercial and medical
roles at GSK, Organon and Byk Gulden.
Ms. Sharon Elizabeth Tetlow, MBA, based in the
U.S., has more than three decades of experience specializing in
finance within the life sciences industry. Ms. Tetlow founded and
serves as Managing Partner of Potrero Hill Advisors (PHA). In her
role at PHA and through her career as a serial CFO, she has lead
and executed successful financial strategies. Prior to PHA,
Ms. Tetlow was managing director of Danforth Advisors, a similar
financial advisory firm and held previous CFO/senior finance roles
at Cell Genesys, Pathwork Dx, diaDexus, among others. She currently
serves as Audit Committee Chair on the Board of Directors of
Catalyst Biosciences (NASDAQ:CBIO) and on the board of Katherine
Michiels School Project Open Mind, an education-related
not-for-profit in San Francisco. Ms. Tetlow earned a B.A. from the
University of Delaware and M.B.A. from Stanford University.
Alexander von Gabain, Ms. Lisa Shaw-Marotto and
Ms. Sandra Poole have stepped down from Valneva’s Supervisory
Board. Alexander Von Gabain will be appointed to Valneva’s
Scientific Advisory Board (SAB) and will remain an observer to the
Supervisory Board.
Thomas Lingelbach, CEO of Valneva
commented, “We welcome Johanna and Sharon to Valneva and are
thrilled to have such highly accomplished individuals aboard as our
two leading programs against Lyme disease and chikungunya are
approaching late stage development. We would like to thank Lisa and
Sandra for their great contributions helping to shape the company´s
success. Alexander´s new role will create an important link between
the Scientific Advisory Board and Supervisory Board.”
Valneva also confirmed at its AGM that it
expects to announce first Phase 2 results of its Lyme vaccine
candidate in July 2020, initiate Phase 3 clinical studies for its
chikungunya vaccine candidate in the U.S. later this year, and that
preclinical activity on the SARS-COV-2 vaccine candidate is
progressing. Valneva aims to initiate clinical studies for this
vaccine candidate before the end of 2020, subject to successful
remaining pre-clinical work and receipt of appropriate funding.
The AGM’s voting results will be made available
in the “Investors & Media” section of Valneva’s corporate
website in the coming days.
About Valneva SEValneva is a specialty
vaccine company focused on prevention against diseases with major
unmet needs. Valneva’s portfolio includes two commercial vaccines
for travelers: IXIARO®/JESPECT® indicated for the prevention of
Japanese encephalitis and DUKORAL® indicated for the prevention of
cholera and, in some countries, prevention of diarrhea caused by
ETEC. The Company has various vaccines in development including
unique vaccines against Lyme disease and chikungunya. Valneva has
operations in Austria, Sweden, the United Kingdom, France, Canada
and the U.S. with over 500 employees. For more information, visit
www.valneva.com and follow the company on LinkedIn.
Valneva
Investor and Media ContactsLaetitia Bachelot-FontaineGlobal
Head of Investor Relations & Corporate CommunicationsM +33 (0)6
4516 7099investors@valneva.com |
|
Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2020_06_17_Valneva_Post_AGM_PR_EN_Final
Grafico Azioni Valneva (EU:VLA)
Storico
Da Feb 2024 a Mar 2024
Grafico Azioni Valneva (EU:VLA)
Storico
Da Mar 2023 a Mar 2024